. Author manuscript; available in PMC: 2012 Oct 24.

Published in final edited form as: Arch Intern Med. 2011 Jul 25;171(19):1712–1718. doi: 10.1001/archinternmed.2011.351

Table 3.

Discrimination and Reclassification for the Comparison of Models including HbA1c to Classification of Diabetes as a Cardiovascular Risk Equivalent in Diabetic Participants

	ATP III	RRS
Women’s Health Study
C-statistic for Risk Equivalent	0.515	0.519
C-statistic for model with HbA1c	0.692	0.697
P value for C-statistic comparison	<0.001	<0.001
NRI (p value)	26.7% (0.001)	23.6% (0.003)
IDI (p value)	0.072 (<0.001)	0.072 (<0.001)
Reclassification χ² for Risk Equivalent (p value)	37.6 (<0.001)	35.9 (<0.001)
Reclassification χ² for model with HbA1c (p value)	14.4 (0.002)	15.9 (0.001)
Physician’s Health Study II
C-statistic for Risk Equivalent	0.563	0.578
C-statistic for model with HbA1c	0.602	0.605
P value for C-statistic comparison	0.015	0.081
NRI (p value)	9.2 % (0.042)	12.4 % (0.005)
IDI (p value)	0.039 (<0.001)	0.041 (<0.001)
Reclassification χ² for Risk Equivalent (p value)	26.5 (<0.001)	27.1 (<0.001)
Reclassification χ² for model with HbA1c (p value)	9.8 (0.002)	6.5 (0.011)

ATP III = base covariates from Adult Treatment Panel III, RRS = base covariates from Reynolds risk score